BiVictriX Therapeutrics PLC announced on Monday that it had received positive final data from a second in vivo efficacy study of BVX001, an antibody drug for treatment of acute myeloid leukaemia..
Bivictrix Therapeutics PLC - Macclesfield, England-based biotechnology company focusing on cancer therapies - Posts positive interim data in its second preclinical efficacy study of its lead. | June 19, 2023
Bivictrix Therapeutics PLC - Macclesfield, England-based biotechnology company focusing on cancer therapies - Nominates a clinical candidate for its BVX001 programme after data from a clinical study. | June 6, 2023
TRADING UPDATES: Bivictrix hails cancer therapy candidate lse.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lse.co.uk Daily Mail and Mail on Sunday newspapers.